US EditionTargeted in Vivo Gene Integration of a Secretion-Enabled GLP-1 Receptor Agonist Reverses Diet-Induced Non-Genetic Obesity and Pre-Diabetes
JAPAN, JUL 9 – Researchers created a one-time genome editing treatment enabling mice to produce weight-loss drugs internally, potentially improving adherence and reducing treatment duration, study shows.
7 Articles
7 Articles
Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes
In vivo genome editing offers a long-term therapeutic approach for monogenic diseases by directly modifying genetic sequences. However, its application to non-monogenic, noncommunicable diseases, which are the leading causes of global mortality, remains limited due to the lack of well-defined genetic targets. We developed an in vivo genome-editing approach to introduce a gene encoding the glucagon-like peptide-1 (GLP-1) receptor agonist Exendin-4
Genome editing enables mice to produce their own weight-loss drug for months
Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.
sport.es
elcorreoweb.esIn recent years, drugs such as Ozempic have led to a genuine medical revolution in the treatment of obesity and type 2 diabetes. These drugs act by imitating the function of LPG-1; a hormone that regulates appetite and glucose levels, to reduce hunger, improve blood sugar control and promote weight loss. Its creators claim that these tools can achieve "spectacular" results but that, in order to achieve all its benefits and maintain its effects, …
That's an excellent alternative to Ozempic.
Obesity Reversed In Genome Edited Mice That Produce Their Own GLP-1 - Data Intelligence
Weight-loss and diabetes drugs like GLP-1 receptor agonists have reshaped the treatment landscape, but they come with a catch: frequent injections to maintain their effects. Now, researchers in Japan have taken a striking step toward rewriting this paradigm by turning the liver into a long-term GLP-1 producer. In a study titled “Targeted In Vivo Gene Integration of a Secretion-Enabled GLP-1 Receptor Agonist Reverses Diet-induced Non-genetic Obes…
Obesity Reversed in Genome Edited Mice that Produce Their Own GLP-1
Weight-loss and diabetes drugs like GLP-1 receptor agonists have reshaped the treatment landscape, but they come with a catch: frequent injections to maintain their effects. Now, researchers in Japan have taken a striking step toward rewriting this paradigm by turning the liver into a long-term GLP-1 producer. In a study titled “Targeted In Vivo Gene Integration of a Secretion-Enabled GLP-1 Receptor Agonist Reverses Diet-induced Non-genetic Obes…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
